<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">OJMM</journal-id><journal-title-group><journal-title>Open Journal of Medical Microbiology</journal-title></journal-title-group><issn pub-type="epub">2165-3372</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.4236/ojmm.2016.62011</article-id><article-id pub-id-type="publisher-id">OJMM-67583</article-id><article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Medicine&amp;Healthcare</subject></subj-group></article-categories><title-group><article-title>
 
 
  A Study on Isolation and Antibiotic Sensitivity Testing of &lt;i&gt;Pseudomonas aeruginosa&lt;/i&gt; Isolated from Patients with Respiratory Tract Infection with Special Reference to Phenotypic and Genotypic Characterization of Extended Spectrum Beta Lactamases (ESBL)
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>P.</surname><given-names>A. Shiny</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>S.</surname><given-names>Rajendran</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Y.</surname><given-names>Lakshmi Sarayu</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib></contrib-group><aff id="aff1"><addr-line>Registar in Microbiology, Public Health Laboratory, Ministry of Health, Kuwait City, Kuwait</addr-line></aff><aff id="aff2"><addr-line>Division of Microbiology, Rajah Muthiah Medical College, Annamalai University, Chidambaram, India</addr-line></aff><pub-date pub-type="epub"><day>15</day><month>06</month><year>2016</year></pub-date><volume>06</volume><issue>02</issue><fpage>80</fpage><lpage>86</lpage><history><date date-type="received"><day>19</day>	<month>March</month>	<year>2016</year></date><date date-type="rev-recd"><day>accepted</day>	<month>19</month>	<year>June</year>	</date><date date-type="accepted"><day>22</day>	<month>June</month>	<year>2016</year></date></history><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  Backgrounds: 
  Pseudomonas aeruginosa is a classic opportunistic pathogen with innate resistance to many antibiotics and disinfectants. The lung is a main target for colonization and infection by the bacteria either in the context of a chronic, progressively deteriorating infectious and inflammatory pulmonary disease such as cystic fibrosis (CF) or in a more acute setting such as severe pneumonia in immunocompromised patients [1]. Aim and Objectives: To study the prevalence, virulence and the resistance pattern, phenotypic and genotypic characterization of 
  P. aeruginosa from sputum samples. 
  Materials and Methods: The present study was carried out with a total of 500 clinical sputum samples, which were received from patients, admitted to the various departments of Rajah Muthiah Medical College &amp; Hospital, Annamalai University, Chidambaram. 
  Result: Of the 500 samples subjected for isolation and identification of 
  P. aeruginosa, 116 (23.20%) were positive. The isolated strains were tested for antibiotic sensitivity patterns. 93.10% of 
  P. aeruginosa showed a maximum sensitivity to Ofloxacin, Norfloxacin and 86.20% of strains were highly resistant to Cefotaxime. The same isolates were also tested for phenotypic characterization of Extended Spectrum of Beta Lactamases by double disc synergy method against Cefotaxime and Clavulanic acid, according to the criteria of Hi-Media [2]. Of the resistant strains of 
  P. aeruginosa isolated from sputum, 59% were positive for ESBL. The genotype characterization of ESBL 
  P. aeruginosa showed 40% of CTX-M and 46.66% SHV gene. 
  Conclusion: The present study strongly recommends for further checking of the antibiotic resistant strains of 
  P. aeruginosa for phenotypic characterization of ESBL for effective treatment.
 
</p></abstract><kwd-group><kwd>&lt;i&gt;Pseudomonas aeruginosa&lt;/i&gt;</kwd><kwd> Prevalence in Patient with Respiratory Tract Infection (RTI)</kwd><kwd> Socioeconomic Status</kwd><kwd> ESBL</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>1. Introduction</title><p>P. aeruginosa is an aerobic gram-negative, motile, non-spore forming rods that are oxidase positive and lactose nonfermenters. P. aeruginosa is a member of the genus Pseudomonas. It is hydrophilic and widely distributed in nature. It forms smooth fluorescent green colonies at 42˚C, with a characteristic sweet (grape-like) odor, making it easy to recognize on solid media in the laboratory. It is a common bacterium which causes respiratory tract infection in humans [<xref ref-type="bibr" rid="scirp.67583-ref3">3</xref>] . Nowadays, P. aeruginosa is producing resistance to all antibiotic by the production of Extended Spectrum Beta Lactamase due to hyper production of Broad Spectrum B-lactamases, decreased outer membrane permeability and active efflux [<xref ref-type="bibr" rid="scirp.67583-ref4">4</xref>] . It is found that high prevalence of multidrug resistance and extended spectrum Beta lactamase strains in hospital [<xref ref-type="bibr" rid="scirp.67583-ref5">5</xref>] .</p><p>This study was conducted to correlate the prevalence, sex, age, socio-economic, domicile status, fluorescence and non fluorescence strain, virulence, antibiotic sensitivity, phenotypic and genotypic characterization of Extended Spectrum Beta Lactmase (ESBL) of P. aeruginosa causing respiratory tract infection among the patient attending Rajah Muthiah Medical Collage and Hospital, Chidambaram, Cuddalore District, Tamil Nadu, India.</p></sec><sec id="s2"><title>2. Materials and Methods</title><p>A total of 500 Sputum samples were collected from patients admitted to the Rajah Muthiah Medical College and Hospital, Chidambaram, Cuddalore District, Tamil Nadu. The sputum samples were collected from the department of Chest medicine, and Pediatrics. Patients presented with various lung diseases such as chronic bronchitis, bronchiectasis, cystic fibrosis, bronchial asthma, fibrosing alveolitis, pulmonary tuberculosis and healed tuberculosis with fungal super infections.</p><p>The specimens collected were expectorated sputum and bronchial washings. The sputum samples were collected on the three consecutive days in a sterile wide mouthed container and processed immediately.</p><p>The specimen were examined microscopically in gram’s stained smear and cultured for aerobic pathogens by standard procedures. Presumptively identified by colony morphology, pigment production and the characteristic musty or earthy odor and confirmed by motility and by other biochemical tests. Antimicrobial susceptibility pattern was tested for the following antibiotics namely, Gentamicin (G), Amikacin (AK), Cefepime (Cpm), Cephotaxime (CE), Aztreonam(Ao), Meropenem (M1), Imipenem (I) Tobramycin (TB), Ofloxacin (OF), Norfloxacin (NX) Ticarcillin (Ti) by Kirby-Bauer’s disc-diffusion technique [<xref ref-type="bibr" rid="scirp.67583-ref6">6</xref>] . The pattern was graded into sensitive, intermediate and resistant, according to standard sensitivity charts from Hi-media. The fluorescence and non fluorescence strain of P. Aeruginosa were studied. The extracellular virulence factors such as Haemolysin, Protease, DNAse, Gelatinase, Lipase and Amylase were also studied. The P. aeruginosa was also tested for phenotypic characterization of extended spectrum Beta lactamase by double disc synergy method against Ceftazidime and Clavulanic acid, according to criteria of Hi-media [<xref ref-type="bibr" rid="scirp.67583-ref2">2</xref>] . The genotypic characterization of extended spectrum Beta lactamase was done by polymerized chain reactions.</p></sec><sec id="s3"><title>3. Results</title><p>A total of 500 sputum samples were screened for aerobic bacteria. Of the 500 sputum samples screened, 72% were positive for bacterial isolates. Among the bacterial isolates, the P. aeruginosa (23.20%) Streptococcus (2.2%) Staphylococcus aureus (4%), Escherichia coli (13.66%), Klebsiella pneumoniae (27%), Proteus mirabilis (0.6%), Enterococci (0.3%) (<xref ref-type="fig" rid="fig1">Figure 1</xref> and <xref ref-type="table" rid="table1">Table 1</xref>).</p><p>The sex wise distribution for P. aeruginosa positive cases showed, 57.75% of infected males and 42.25 % of infected females (<xref ref-type="fig" rid="fig2">Figure 2</xref>).</p><p>Both males and females, showed a higher percentage positivity for P. aeruginosa in the age groups of 61-75 (39.28%) years and 76 - 90 (33.34%) years. The percentage positivity for P. aeruginosa patients belonging to the age group of 61 - 75 years, was also found to be statistically significant (P = 0.005) (<xref ref-type="table" rid="table2">Table 2</xref>).</p><p>Of the 116 P. aeruginosa positive cases, 57 cases (49.13%) were coolies, among which, 47 cases were males. Most of the infected females, 39 cases (33.62%), were housewives (<xref ref-type="table" rid="table3">Table 3</xref>).</p><p>The percentage of P. aeruginosa positive respiratory tract infection cases, according to the domicile status of the patients, were as follows, with 53% seen in rural areas, 34% in urban areas and 13% of cases seen in semi urban areas (<xref ref-type="fig" rid="fig3">Figure 3</xref>).</p><p>In sputum, 93.10% of strains were sensitive to ofloxacin and norfloxacin, 79.32% to tobramycin, 73% to ciprofloxacin, 63.80% to gentamicin, amikacin, meropenem and imipenem, 57.75% to ticarcillin and 56.90% to cefepime. The 86.20% of cases were resistant to cefotaxime, 59% to cefatazidime and 57.75% to aztreonam (<xref ref-type="table" rid="table4">Table 4</xref>).</p><p>93.11% of the P. aeruginosa, showed multi drug resistance and 6.89% showed single drug resistance (<xref ref-type="table" rid="table5">Table 5</xref>).</p><p>The percentage of Extended Spectrum Beta Lactamase (ESBL) positive P. aeruginosa was 59% (<xref ref-type="table" rid="table6">Table 6</xref>).</p><p>Of the 116 strains isolated, 15 strains were randomly chosen and tested for fluorescence and non fluorescence producing strains (<xref ref-type="table" rid="table7">Table 7</xref>), for the production of extracellular virulence factors and also, for the expression of ESBL gene (bla CTX-M, bLa SHV).</p><p>93.33% of the strains produced haemolysin, protease and lipase whereas only 73.33% of the strains produced DNAse and gelatinase (<xref ref-type="table" rid="table8">Table 8</xref>).</p><p>The genotype characterization showed 40% of CTX-M and 46.66% SHV gene in Ps. aeruginosa, isolated from sputum (n = 15) (<xref ref-type="table" rid="table9">Table 9</xref>).</p><fig id="fig1"  position="float"><label><xref ref-type="fig" rid="fig1">Figure 1</xref></label><caption><title> The prevalence of Pseudomonas aeruginosa and other bacterial isolates in respiratory tract infection (n = 500)</title></caption><graphic mimetype="image"   position="float"  xlink:type="simple"  xlink:href="http://html.scirp.org/file/4-2260230x6.png"/></fig><fig id="fig2"  position="float"><label><xref ref-type="fig" rid="fig2">Figure 2</xref></label><caption><title> Sex wise distribution of Pseudomonas aeruginosa positive cases (n = 116)</title></caption><graphic mimetype="image"   position="float"  xlink:type="simple"  xlink:href="http://html.scirp.org/file/4-2260230x7.png"/></fig><fig id="fig3"  position="float"><label><xref ref-type="fig" rid="fig3">Figure 3</xref></label><caption><title> Distribution of Pseudomonas aeruginosa positive cases according to domicile status</title></caption><graphic mimetype="image"   position="float"  xlink:type="simple"  xlink:href="http://html.scirp.org/file/4-2260230x8.png"/></fig><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Isolation of bacteria from sputum (n = 500)</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >S. No</th><th align="center" valign="middle" >Bacteria isolated</th><th align="center" valign="middle" >No. of isolates</th><th align="center" valign="middle" >%</th></tr></thead><tr><td align="center" valign="middle" >1.</td><td align="center" valign="middle" >Pseudomonas aeruginosa</td><td align="center" valign="middle" >116</td><td align="center" valign="middle" >23.20%</td></tr><tr><td align="center" valign="middle" >2.</td><td align="center" valign="middle" >Klebsiella pneumoniae</td><td align="center" valign="middle" >135</td><td align="center" valign="middle" >27%</td></tr><tr><td align="center" valign="middle" >3.</td><td align="center" valign="middle" >Escherichia coli</td><td align="center" valign="middle" >68</td><td align="center" valign="middle" >13.66%</td></tr><tr><td align="center" valign="middle" >4.</td><td align="center" valign="middle" >Staphylococcus aureus</td><td align="center" valign="middle" >20</td><td align="center" valign="middle" >4%</td></tr><tr><td align="center" valign="middle" >5.</td><td align="center" valign="middle" >Streptococcus</td><td align="center" valign="middle" >11</td><td align="center" valign="middle" >2.2%</td></tr><tr><td align="center" valign="middle" >6.</td><td align="center" valign="middle" >Proteus mirabilis</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >0.6%</td></tr><tr><td align="center" valign="middle" >7.</td><td align="center" valign="middle" >Enterococci</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >0.4%</td></tr><tr><td align="center" valign="middle"  colspan="2"  >Total No. of bacterial isolates</td><td align="center" valign="middle" >217</td><td align="center" valign="middle" >72.33%</td></tr><tr><td align="center" valign="middle"  colspan="2"  >No growth</td><td align="center" valign="middle" >140</td><td align="center" valign="middle" >28%</td></tr></tbody></table></table-wrap><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Age wise distribution of Pseudomonas aeruginosa positive respiratory tract infection cases [sputum n = 116]</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Age group</th><th align="center" valign="middle" >No. of cases screened</th><th align="center" valign="middle" >No. of positive cases</th><th align="center" valign="middle" >No. of negative cases</th></tr></thead><tr><td align="center" valign="middle" >0 - 15</td><td align="center" valign="middle" >10 (2%)</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >10 (100%)</td></tr><tr><td align="center" valign="middle" >16 - 30</td><td align="center" valign="middle" >124 (24.8%)</td><td align="center" valign="middle" >17 (13.71%)</td><td align="center" valign="middle" >107 (86.29%)</td></tr><tr><td align="center" valign="middle" >31 - 45</td><td align="center" valign="middle" >134 (26.8%)</td><td align="center" valign="middle" >33 (24.62%)</td><td align="center" valign="middle" >101 (75.38%)</td></tr><tr><td align="center" valign="middle" >46 - 60</td><td align="center" valign="middle" >124 (24.8%)</td><td align="center" valign="middle" >25 (20.16%)</td><td align="center" valign="middle" >99 (79.84%)</td></tr><tr><td align="center" valign="middle" >61 - 75</td><td align="center" valign="middle" >84 (16.8%)</td><td align="center" valign="middle" >33 (39.28%)<sup>*</sup></td><td align="center" valign="middle" >51 (60.72%)</td></tr><tr><td align="center" valign="middle" >76 - 90</td><td align="center" valign="middle" >24 (4.8%)</td><td align="center" valign="middle" >8 (33.34%)</td><td align="center" valign="middle" >16 (66.66%)</td></tr><tr><td align="center" valign="middle" >Total</td><td align="center" valign="middle" >500</td><td align="center" valign="middle" >116 (23.2%)</td><td align="center" valign="middle" >384 (76.8%)</td></tr></tbody></table></table-wrap><p><sup>*</sup>(S)―significant.</p><table-wrap id="table3" ><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> Profession wise distribution of P. aeruginosa positive cases (n = 116)</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >S. No</th><th align="center" valign="middle" >Occupation</th><th align="center" valign="middle" >Male</th><th align="center" valign="middle" >Female</th><th align="center" valign="middle" >Total No. of P. aeruginosa positive cases</th></tr></thead><tr><td align="center" valign="middle" >1</td><td align="center" valign="middle" >Coolie</td><td align="center" valign="middle" >47</td><td align="center" valign="middle" >10</td><td align="center" valign="middle" >57 (49.13%)</td></tr><tr><td align="center" valign="middle" >2</td><td align="center" valign="middle" >Driver</td><td align="center" valign="middle" >20</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >20 (17.25%)</td></tr><tr><td align="center" valign="middle" >3</td><td align="center" valign="middle" >Housewife</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >39</td><td align="center" valign="middle" >39 (33.62%)</td></tr><tr><td align="center" valign="middle"  colspan="2"  >Total No. of P. aeruginosa positive cases</td><td align="center" valign="middle" >67 (57.75%)</td><td align="center" valign="middle" >49 (42.25%)</td><td align="center" valign="middle" >116</td></tr></tbody></table></table-wrap><table-wrap id="table4" ><label><xref ref-type="table" rid="table4">Table 4</xref></label><caption><title> Antibiogram pattern of 116 strains isolated from sputum (n = 116)</title></caption><table><tbody><thead><tr><th align="center" valign="middle"  rowspan="2"  >Groups</th><th align="center" valign="middle"  rowspan="2"  >Antibiotic Tested</th><th align="center" valign="middle"  colspan="2"  >Sputum (n = 116)</th></tr></thead><tr><td align="center" valign="middle" >Sensitive</td><td align="center" valign="middle" >Resistance</td></tr><tr><td align="center" valign="middle"  rowspan="3"  >Aminoglycosides</td><td align="center" valign="middle" >Gentamicin [G]</td><td align="center" valign="middle" >74 (63.80%)</td><td align="center" valign="middle" >42 (36.20%)</td></tr><tr><td align="center" valign="middle" >Amikacin [Ak]</td><td align="center" valign="middle" >74 (63.80%)</td><td align="center" valign="middle" >42 (36.20%)</td></tr><tr><td align="center" valign="middle" >Tobramycin [Tb]</td><td align="center" valign="middle" >92 (79.32%)</td><td align="center" valign="middle" >24 (20.68%)</td></tr><tr><td align="center" valign="middle"  rowspan="3"  >Fluroquinolones</td><td align="center" valign="middle" >Ciprofloxacin[Ci]</td><td align="center" valign="middle" >85 (73%)</td><td align="center" valign="middle" >31 (27%)</td></tr><tr><td align="center" valign="middle" >Ofloxacin [Of]</td><td align="center" valign="middle" >108 (93.10%)</td><td align="center" valign="middle" >8 (6.90%)</td></tr><tr><td align="center" valign="middle" >Norfloxacin [Nx]</td><td align="center" valign="middle" >108 (93.10%)</td><td align="center" valign="middle" >8 (6.90%)</td></tr><tr><td align="center" valign="middle"  rowspan="2"  >Carbapenems</td><td align="center" valign="middle" >Meropenem [Mi]</td><td align="center" valign="middle" >74 (63.80%)</td><td align="center" valign="middle" >42 (36.20%)</td></tr><tr><td align="center" valign="middle" >Imipenem [I]</td><td align="center" valign="middle" >74 (63.80%)</td><td align="center" valign="middle" >42 (36.20%)</td></tr><tr><td align="center" valign="middle" >Extended Spectrum Penicillin</td><td align="center" valign="middle" >Ticarcillin [Ti]</td><td align="center" valign="middle" >67 (57.75%)</td><td align="center" valign="middle" >49 (42.25%)</td></tr><tr><td align="center" valign="middle" >Monobactams</td><td align="center" valign="middle" >Aztreonam [Ao]</td><td align="center" valign="middle" >49 (42.25%)</td><td align="center" valign="middle" >67 (57.75%)</td></tr><tr><td align="center" valign="middle"  rowspan="3"  >Cephalosporins</td><td align="center" valign="middle" >Cefepime [Cpm]</td><td align="center" valign="middle" >66 (56.90%)</td><td align="center" valign="middle" >50 (43.10%)</td></tr><tr><td align="center" valign="middle" >Cephotaxime [Ce]</td><td align="center" valign="middle" >16 (13.80%)</td><td align="center" valign="middle" >100 (86.20%)</td></tr><tr><td align="center" valign="middle" >Cefatazidime [Ca]</td><td align="center" valign="middle" >47 (41%)</td><td align="center" valign="middle" >69 (59%)</td></tr></tbody></table></table-wrap><table-wrap id="table5" ><label><xref ref-type="table" rid="table5">Table 5</xref></label><caption><title> Expression of antibiotic resistance pattern of Pseudomonas aeruginosa isolated from sputum against 13 antibiotics</title></caption><table><tbody><thead><tr><th align="center" valign="middle"  rowspan="2"  >Type of drug resistance pattern against 13 antibiotics used</th><th align="center" valign="middle" >Percentage of resistance pattern of Pseudomonas aeruginosa from different samples against 13 antibiotics used</th></tr></thead><tr><td align="center" valign="middle" >Sputum (n = 116)</td></tr><tr><td align="center" valign="middle" >Multi drug resistance</td><td align="center" valign="middle" >108 (93.11%)</td></tr><tr><td align="center" valign="middle" >Single drug resistance</td><td align="center" valign="middle" >8 (6.89%)</td></tr></tbody></table></table-wrap><table-wrap id="table6" ><label><xref ref-type="table" rid="table6">Table 6</xref></label><caption><title> Extended spectrum beta lactamase producing Pseudomonas aeruginosa by synergy test</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Specimen</th><th align="center" valign="middle" >ESBL %</th></tr></thead><tr><td align="center" valign="middle" >Sputum (n = 116)</td><td align="center" valign="middle" >69 (59%)</td></tr></tbody></table></table-wrap><table-wrap id="table7" ><label><xref ref-type="table" rid="table7">Table 7</xref></label><caption><title> Fluorescence and non fluorescence producing Pseudomonas aeruginosa from sputum (n = 15)</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Category according to fluorescence</th><th align="center" valign="middle" >Sputum (n = 15)</th></tr></thead><tr><td align="center" valign="middle" >Fluorescence</td><td align="center" valign="middle" >11 (73.34%)</td></tr><tr><td align="center" valign="middle" >Non fluorescence</td><td align="center" valign="middle" >4 (26.66%)</td></tr><tr><td align="center" valign="middle" >Total</td><td align="center" valign="middle" >15</td></tr></tbody></table></table-wrap><table-wrap id="table8" ><label><xref ref-type="table" rid="table8">Table 8</xref></label><caption><title> Production of extracellular virulence factors by Pseudomonas aeruginosa isolated from sputum (n = 15)</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >No. of Pseudomonas aeruginosa</th><th align="center" valign="middle" >Haemolysin</th><th align="center" valign="middle" >Protease</th><th align="center" valign="middle" >DNAse</th><th align="center" valign="middle" >Gelatinase</th><th align="center" valign="middle" >Lipase</th><th align="center" valign="middle" >Amylase</th></tr></thead><tr><td align="center" valign="middle" >Sputum n = 15</td><td align="center" valign="middle" >14 (93.33%)</td><td align="center" valign="middle" >14 (93.33%)</td><td align="center" valign="middle" >11 (73.33%)</td><td align="center" valign="middle" >11 (73.33%)</td><td align="center" valign="middle" >14 (93.33%)</td><td align="center" valign="middle" >0 (0%)</td></tr></tbody></table></table-wrap><table-wrap id="table9" ><label><xref ref-type="table" rid="table9">Table 9</xref></label><caption><title> Expression of ESBL genes by Pseudomonas aeruginosa strains isolated from sputum (n = 15)</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >ESBL genes expressed</th><th align="center" valign="middle" >Strains expressing ESBL genes</th><th align="center" valign="middle" >Percentage</th></tr></thead><tr><td align="center" valign="middle" >bla CTX-M</td><td align="center" valign="middle" >6 strains (S<sub>1</sub>, S<sub>5</sub>, S<sub>8</sub>, S<sub>10</sub>, S<sub>11</sub>, S<sub>15</sub>)</td><td align="center" valign="middle" >40%</td></tr><tr><td align="center" valign="middle" >bLa SHV</td><td align="center" valign="middle" >7 strains (S<sub>1</sub>, S<sub>5</sub>, S<sub>7</sub>, S<sub>8</sub>, S<sub>10</sub>, S<sub>11</sub>, S<sub>15</sub>)</td><td align="center" valign="middle" >46.66%</td></tr></tbody></table></table-wrap></sec><sec id="s4"><title>4. Discussion</title><p>Pseudomonas aeruginosa infection occurs all over human and animal body. P. aeruginosa is the predominant respiratory tract pathogen in patients with cystic fibrosis and other chronic infections [<xref ref-type="bibr" rid="scirp.67583-ref3">3</xref>] . P. aeruginosa develops acquired resistance easily, either by mutation in chromosomally-encoded gene transfer or by the horizontal gene transfer of antibiotic resistance determinants. One of the most worrisome characteristics of Ps. aeruginosa is its low antibiotic susceptibility. The phenotypic resistance is associated to emergence of small colony variant and biofilm formation in P. aeruginosa. [<xref ref-type="bibr" rid="scirp.67583-ref7">7</xref>]</p><p>The present study showed that in 500 sputum samples, 23.20% were positive for P. aeruginosa and other Bacterial isolates were 72%. P. aeruginosa is a common contaminant in the environment and showed higher percentage positivity in sputum. The sex wise distribution of P. aeruginosa positive cases was males (57.75%) and females (42.25%). When compared to females, males were more prone to pseudomonas infection because of their increased exposure to various adverse environmental factors.</p><p>The higher percentage positivity of P. aeruginosa was seen in the age group 61 - 75 years (39.28%). P. aeruginosa a major opportunistic pathogen in humans and is capable of infecting various tissues and organs and causing severe, damaging, and often fatal disease [<xref ref-type="bibr" rid="scirp.67583-ref8">8</xref>] .</p><p>The study also indicated that a prevalence of P. aeruginosa in rural (53%) and urban (34%) areas. This is because in urban areas, people are more affected due to pollution, industrialization, precipitating factors and hospital acquired infection.</p><p>Among the antibiotics tested, the isolates were highly sensitive to Ofloxacin and Norfloxacin (86.20%) and highly resistant to Cephotaxime (86.20%). Since the antibiotic Cephotaxime was used commonly by the clinician, P. aeruginosa developed resistance [<xref ref-type="bibr" rid="scirp.67583-ref9">9</xref>] .</p><p>In the present study, the P. aeruginosa isolated from respiratory tract infection was showing 73.34% fluorescence positive P. aeruginosa and 26.66% nonfluorescence strains. The present study also revealed that the percentage of fluorescence strains were predominantly isolated from respiratory tract infection like other studies [<xref ref-type="bibr" rid="scirp.67583-ref10">10</xref>] . Among the P. aeruginosa isolated from sputum, the production of haemolysin, protease and lipase was 93.33%, DNAse and gelatinase was 73.33%. Also the study revealed that there was correlation between the production of extracellular virulence and multi drug resistance [<xref ref-type="bibr" rid="scirp.67583-ref11">11</xref>] .</p><p>A study was also conducted for Extended Spectrum Beta Lactamase producing P. aeruginosa among the drug Cephotaxime with Clavulanic drug and 59% Cephotaxime resistant strain showed ESBL positive [<xref ref-type="bibr" rid="scirp.67583-ref12">12</xref>] . In our study the genotype characterization showed 40% of CTX-M and 46.66% showed SHV expressing gene of P. aeruginosa.</p></sec><sec id="s5"><title>5. Conclusion</title><p>Pseudomonas aeruginosa is the second most common cause of respiratory tract infections. It is one of the most common opportunistic pathogens with multidrug resistant. Moreover, the present study strongly recommends for further checking of the antibiotic resistant strains of P. aeruginosa for phenotypic characterization of ESBL for effective treatment.</p></sec><sec id="s6"><title>Cite this paper</title><p>P. A. Shiny,S. Rajendran,Y. Lakshmi Sarayu, (2016) A Study on Isolation and Antibiotic Sensitivity Testing of Pseudomonas aeruginosa Isolated from Patients with Respiratory Tract Infection with Special Reference to Phenotypic and Genotypic Characterization of Extended Spectrum Beta Lactamases (ESBL). Open Journal of Medical Microbiology,06,80-86. doi: 10.4236/ojmm.2016.62011</p></sec></body><back><ref-list><title>References</title><ref id="scirp.67583-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Knapp, S., Schultz, M.J. and van der Poll, T. (2005) Pneumonia Models and Innate Immunity to Respiratory Bacterial Pathogens. Shock, 24, 12-18. http://dx.doi.org/10.1097/01.shk.0000191385.41689.f3</mixed-citation></ref><ref id="scirp.67583-ref2"><label>2</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Livermore</surname><given-names> D.M. </given-names></name>,<etal>et al</etal>. (<year>1995</year>)<article-title>Beta-Lactamases Laboratory and Clinical Resistance</article-title><source> Clinical Microbiology Reviews</source><volume> 8</volume>,<fpage> 557</fpage>-<lpage>584</lpage>.<pub-id pub-id-type="doi"></pub-id></mixed-citation></ref><ref id="scirp.67583-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Chastre, J. and Fasgon, Y. (2002) Ventilator-Associated Pneumonia. American Journal of Respiratory and Critical Care Medicine, 165, 867-903. http://dx.doi.org/10.1164/ajrccm.165.7.2105078</mixed-citation></ref><ref id="scirp.67583-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Poole, K. (2007) Efflux Pumps as Antimicrobial Resistance Mechanism. Annals of Medicine, 39, 162-176.http://dx.doi.org/10.1080/07853890701195262</mixed-citation></ref><ref id="scirp.67583-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Govan, J.R. and Deretic, V. (1996) Microbial Pathogenesis in Cystic Fibrosis: Mucoid Pseudomonas aeruginosa and Burkholderia cepacia. Microbiological Reviews, 60, 539-574.</mixed-citation></ref><ref id="scirp.67583-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Bauer, A.W, Kirby, W.M.M., Sherries, J.C. and Jurek, M. (1996) Antibiotic Susceptibility Testing by a Standardized Single. Method. American Journal of Clinical Pathology, 54, 493-496.</mixed-citation></ref><ref id="scirp.67583-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Lam, J., Chan, R., Lam, K. and Costerton, J.W. (1980) Production of Mucoid Microcolonies by Pseudomonas aeruginosa within Infected Lungs in Cystic Fibrosis. International Journal of Antimicrobial Agents, 25, 11-25.</mixed-citation></ref><ref id="scirp.67583-ref8"><label>8</label><mixed-citation publication-type="book" xlink:type="simple">Pier, G.B. and Ramphal, R. (2005) Pseudomonas aeruginosa. In: Mandell, G.L., Bennett, J.E. and Dolin, R., Eds., Mandell, Douglas and Bennett’s Principles and Practice of Infectious Disease, 6th Edition, Churchill Livingstone, New York, 2587-2615.</mixed-citation></ref><ref id="scirp.67583-ref9"><label>9</label><mixed-citation publication-type="book" xlink:type="simple">Kiska, D.L. and Gilligan, P.H. (2003) Pseudomonas. In: Murray, P.R., et al., Eds., Manual If Clinical Microbiology, 8th Edition, ASM Press, Washington DC.</mixed-citation></ref><ref id="scirp.67583-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Reyes, E.A., Bale, M.T., Cannon, W.H. and Matsen, J.M. (1981) Identification of Pseudomonas Aeruginosa by Pyocyanin Production on Tech Agar. Journal of Clinical Microbiology, 13, 456-458.</mixed-citation></ref><ref id="scirp.67583-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Thangam, M., Rajendran, S., Subramanian, S. and Deivanayagam, C.N. (1987) Production of Extracellular Virulence Factors by Pseudomonas aeruginosa Isolates from Patients with Chronic Lung Disease. A Short Communication. Lung India, 2, 67-69.</mixed-citation></ref><ref id="scirp.67583-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Mathur, P., Kapil, A., Das, B. and Dhawan, B. (2002) Prevalence of Extended Spectrum Beta lactamase Producing Gram Negative Bacteria in a Tertiary Care Hospital. Indian Journal of Medical Research, 115, 153-157.</mixed-citation></ref></ref-list></back></article>